Effects of the Use of an Immersive Virtual Reality Device on Handwriting in Children Aged 6 to 13 With Handwriting Difficulties ( RVALIGO )
Launched by FONDATION ILDYS · Jun 18, 2025
Trial Information
Current as of June 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at whether using an immersive virtual reality (VR) device can help children aged 6 to 13 who have difficulties with handwriting. Handwriting can be hard for some kids, and this can affect their schoolwork and confidence. The researchers want to see if practicing writing skills with fun and interactive VR technology can make learning to write easier and more effective. They will measure different aspects of handwriting, like how steady the writing is and how much pressure the child uses when writing.
Children who have noticeable difficulties with handwriting and are already receiving or will receive therapy to improve their writing may be able to join. Participants need to understand instructions and complete the tests, and cannot have certain health issues like epilepsy or severe vision problems. If children take part, they will use the VR device during training sessions, and their handwriting will be closely evaluated using a special tool. This study hopes to find new ways to support kids struggling with handwriting by making practice more engaging and helpful.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age : 6-13 years
- • BHK: degradation score ≥ 1 standard deviation. The BHK will be administered at the time of the inclusion visit (V1) and/or child with writing difficulties in in daily activities.
- • Children benefiting or to benefit from rehabilitation care to improve handwriting skills.
- • Be able to understand instructions and complete all assessments.
- Exclusion Criteria:
- • Contraindications to using a virtual reality HMD
- • Severe visual impairment
- • Facial injury
- • Epilepsy
- • Lack of parental and/or child consent
About Fondation Ildys
Fondation Ildys is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. Committed to high ethical standards and scientific excellence, the foundation collaborates with healthcare professionals, researchers, and institutions to facilitate the development and evaluation of new treatments across various therapeutic areas. By fostering a culture of collaboration and transparency, Fondation Ildys aims to drive clinical advancements that address unmet medical needs and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brest Cedex 2, , France
Patients applied
Trial Officials
Jéromine HERVO, Coordinator Investigator
Principal Investigator
Fondation Ildys
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported